RxDoctor Payments Data

Parminder Sethi, MD

Urology · Walnut Creek, CANPI 1023041464

Payments from drug & device makers

$24,824in general payments, 2019–2025

Across 362 payments — averaging $68.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$14K
  • Boston Scientific$5K
  • AbbVie$966
  • Antares Pharma, Inc.$703
  • Endo Pharmaceuticals Inc.$607
  • Sumitomo Pharma America, Inc.$434
  • plus $4K from 40 others
$9,103in research payments, 2019–2025

Across 6 payments — averaging $1517.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$9K

What the payments were for

  • Consulting fees$15,60463%
  • Speaking & faculty fees$1,9808%
  • Food & beverage$7,11629%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,824 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$319,358
Medicare patients
629
Services billed
4,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron94$114,932
MyrbetriqMirabegron66$83,753
OrgovyxRelugolix24$65,536
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl70$17,566
XyostedTestosterone Enanthate15$16,700
Dutasteride187$11,886
Tamsulosin Hcl497$7,234
Potassium Citrate ErPotassium Citrate32$3,813
Finasteride274$3,692
Silodosin31$3,644
Testosterone26$3,572
Fesoterodine Fumarate ErFesoterodine Fumarate28$3,028
Solifenacin Succinate31$1,640
Testosterone Cypionate17$1,059
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$434$180,469118 claims
Astellas Pharma US IncMyrbetriq$407$83,75366 claims
Antares Pharma, Inc.Xyosted$703$16,70015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →